Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO OVRAL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO OVRAL 28.
DEMULEN 1/35-28 vs LO/OVRAL-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
None Documented
None Documented
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive